Galapagos traded at 56.20 this Wednesday July 6th, increasing 1.30 or 2.37 percent since the previous trading session. Looking back, over the last four weeks, Galapagos gained 6.44 percent. Over the last 12 months, its price fell by 0.90 percent. Looking ahead, we forecast Galapagos to be priced at 52.55 by the end of this quarter and at 48.17 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
56.20
Daily Change
2.37%
Yearly
-0.90%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
argenx SE 362.70 -5.40 -1.47% 38.01%
AstraZeneca 10,978.00 178.00 1.65% 26.80%
Biogen 215.98 3.40 1.60% -39.22%
Genmab 2,415.00 8.00 0.33% -9.82%
Gilead Sciences 62.73 0.39 0.63% -8.24%
GRIFOLS 16.95 -0.62 -3.50% -23.67%
GlaxoSmithKline 1,790.20 3.60 0.20% 24.58%
Hikma Pharmaceutical 1,682.50 44.50 2.72% -34.74%
Incyte Corp 79.72 0.47 0.59% -2.93%
Merck 171.70 3.85 2.29% 1.63%
Neurocrine Biosciences 95.20 -3.10 -3.15% -3.05%
Novartis 81.22 0.31 0.38% -4.41%
Roche Holding 323.35 4.35 1.36% -9.16%
Sanofi 97.90 0.78 0.80% 12.79%
UCB 85.30 2.70 3.27% -4.16%
Vertex Pharmaceuticals 291.16 2.18 0.75% 46.32%

Indexes Price Day Year
NL25 657 12.49 1.94% -10.97%
BE20 3712 48.69 1.33% -11.15%
EU100 1143 19.03 1.69% -10.05%

Galapagos
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.